Clinical trial
Study of Oral AEE788 in Adults With Advanced Cancer
NCT00118456 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00118456 |
|---|---|
| Title | Study of Oral AEE788 in Adults With Advanced Cancer |
| Official title | A Phase I/II, Multicenter, Randomized Dose-Escalation Study of Oral AEE788 on Intermittent Dosing Schedules in Adult Patients With Advanced Cancer (Effective Amendment 5) Previously Entitled A Phase IA, Multicenter, Dose-Escalating Study of Oral AEE788 on a Continuous Daily Dosing Schedule in Adult… |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | AEE788 |
| Enrollment | 189 |
| Start date | Jul 1, 2003 |
| Primary completion | Jan 1, 2008 |
| First posted | Jul 11, 2005 |
| Last update posted | Jan 9, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: